Connect with us

Hi, what are you looking for?


UK not buying AstraZeneca’s COVID-19 antibody drug over lack of data

The U.K. has no plans to buy doses of AstraZeneca’s COVID-19 antibody therapy Evusheld that is designed to protect vulnerable people, arguing that the data for the drug is insufficient.

“Following a robust review of the available data, our clinical experts advise there is currently insufficient data on the duration of protection offered by Evusheld in relation to the Omicron variant and the government will not be procuring any doses at this time,” a government spokesperson said.

The injection is a combination of two antibodies and is designed to provide long-lasting protection against COVID-19. It was billed as a potential therapy to protect immunocompromised people, since they are unable to generate a strong immune response through vaccination.

AstraZeneca says, however, that there is data showing that Evusheld is effective against the Omicron strains, including BA.1, BA.2, BA.4 and BA.5, while clinical trials carried out before Omicron was first detected late last year showed protection lasted at least six months.

The company also says that evidence from the use of this treatment outside of clinical trials, known as real-world evidence, is accumulating, with the therapy now used to protect people against the virus in 32 countries. Assessing this real-world data is likely to also demonstrate that the therapy provides long-lasting protection for vulnerable people against the current strains, the company argues.

The U.K.’s drugs regulator approved Evusheld for use on March 17, in what was hoped to be a lifeline for vulnerable patients, such as those who’ve had a transplant, cancer patients and people receiving treatment for autoimmune conditions like arthritis.

While the EU has not purchased doses for the bloc, countries including Germany, France and Spain have bought the treatment directly from AstraZeneca.

Meanwhile patient groups in the U.K. have been waiting.

People hearing this news today who have blood cancer or other conditions will be “feeling absolutely devastated,” Helen Rowntree, director of research at Blood Cancer U.K., told the BBC.

Many people are still shielding, unable to see their families, and are “not able to understand why that process is taking so long,” she added.

The government has referred the assessment to the National Institute for Health and Care Excellence, which weighs the costs and benefits of a product for the National Health Service.

It is also keen to see any new data that emerges from the worldwide use of the product.

“We are determined to support the most vulnerable as we live with COVID and immunocompromised patients are a priority for other treatments, access to free tests and vaccination,” the government spokesperson said.

“We continue to explore the market for promising treatments that could prevent infection, to add to the antibody and antiviral treatments that are already offered on the NHS.”

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like


Supporters of a coup against Burkina Faso leader Paul-Henri Sandaogo Damiba attacked the French embassy in the capital Ouagadougou on Sunday. Security forces used...


Press play to listen to this article Splits in the governing U.K. Conservative Party burst into the open Sunday as senior Tory Michael Gove...


At least 174 people have died and more are being treated for injuries following a stampede at a football stadium in Java, Indonesia, on...


King Charles III will not be traveling to Egypt for the COP27 climate summit next month, after U.K. Prime Minister Liz Truss advised him...


DRESDEN — The leader of one of Europe’s most prominent microchips companies on Thursday warned the bloc’s intended investment into the semiconductor industry isn’t...


Press play to listen to this article A long-running campaign to oust World Bank President David Malpass — led by climate hawks within the...


Press play to listen to this article BIRMINGHAM, England — They say absence makes the heart grow fonder — and it’s the absent guests...


Giulia Blasi is a writer and activist based in Rome, and the author of the feminist primer “Manuale per ragazze rivoluzionarie” (Rizzoli, 2018) and...